Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05152914 · ClinicalTrials.gov registry record · Phase 1
Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2
A Phase 1 study of Neuronal Ceroid Lipofuscinosis Type 2, sponsored by David L Rogers, MD.
- Active
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT05152914: Active Phase 1 study of Neuronal Ceroid Lipofuscinosis Type 2, sponsored by David L Rogers, MD.
NCT05152914 is a Phase 1 study of Neuronal Ceroid Lipofuscinosis Type 2 that is active but no longer recruiting, run by David L Rogers, MD. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05152914, a Phase 1 study of Neuronal Ceroid Lipofuscinosis Type 2, is active but no longer recruiting, sponsored by David L Rogers, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase I/II randomized, masked, clinical trial to determine the safety and efficacy of intravitreal administration of cerliponase alfa.
Primary Outcome
Based on the development of unacceptable toxicity, defined as the occurrence of any Grade 3 or higher, unanticipated, treatment related toxicity.
Conditions Studied
Interventions
- DRUG Cerliponase Alfa
Study Locations (1)
Ohio
- Nationwide Children's Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 1 |
What the registry record for NCT05152914 still lists
NCT05152914 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Neuronal Ceroid Lipofuscinosis Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Cerliponase Alfa is the first listed.
NCT05152914 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05152914 about?
NCT05152914 is a clinical study titled "Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2". This is a phase I/II randomized, masked, clinical trial to determine the safety and efficacy of intravitreal administration of cerliponase alfa.
What is the current status of trial NCT05152914?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2021-11-01. Estimated completion is 2027-11-01.
What conditions does trial NCT05152914 study?
This clinical trial studies the following conditions: Neuronal Ceroid Lipofuscinosis Type 2.
What interventions are being tested in trial NCT05152914?
The interventions under investigation include: Cerliponase Alfa (DRUG).
Who is sponsoring clinical trial NCT05152914?
This trial is sponsored by David L Rogers, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05152914 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05152914's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI